^Quaglio G, Lugoboni F, Fornasiero A, Lechi A, Gerra G, Mezzelani P. Dependence on zolpidem: two case reports of detoxification with flumazenil infusion. International Clinical Psychopharmacology. September 2005, 20 (5): 285–7. PMID 16096519. doi:10.1097/01.yic.0000166404.41850.b4.
^Treves N, Perlman A, Kolenberg Geron L, Asaly A, Matok I. Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis. Age and Ageing. March 2018, 47 (2): 201–208. PMID 29077902. doi:10.1093/ageing/afx167.
^Fontaine R, Beaudry P, Le Morvan P, Beauclair L, Chouinard G. Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. International Clinical Psychopharmacology. July 1990, 5 (3): 173–83. PMID 2230061. doi:10.1097/00004850-199007000-00002.
^Stone JR, Zorick TS, Tsuang J. Dose-related illusions and hallucinations with zaleplon. Clinical Toxicology. April 2008, 46 (4): 344–5. PMID 17852167. doi:10.1080/15563650701517442.
^Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS. Central nervous system side effects associated with zolpidem treatment. Clinical Neuropharmacology. 2000, 23 (1): 54–8. PMID 10682233. doi:10.1097/00002826-200001000-00011.
^Yang W, Dollear M, Muthukrishnan SR. One rare side effect of zolpidem--sleepwalking: a case report. Archives of Physical Medicine and Rehabilitation. June 2005, 86 (6): 1265–6. PMID 15954071. doi:10.1016/j.apmr.2004.11.022.
^Liskow B, Pikalov A. Zaleplon overdose associated with sleepwalking and complex behavior. Journal of the American Academy of Child and Adolescent Psychiatry. August 2004, 43 (8): 927–8. PMID 15266187. doi:10.1097/01.chi.0000129219.66563.aa.